Efficacy and Safety of Polycaprolactone Filler in Nonsurgical Rhinoplasty: A Pilot Study.

Background: Nonsurgical rhinoplasty (NSR) is rapidly gaining popularity due to its convenience and lower complication risks. Polycaprolactone (PCL)-based collagen stimulator provides both immediate volumization and long-term neocollagenesis. However, evidence regarding its clinical use in NSR is limited. This study aimed to evaluate the efficacy and safety of PCL-based filler in NSR. Methods: We conducted a single-center, prospective study in which patients received PCL-based filler injection at baseline, followed by a supplementary treatment at 3 months. All participants were followed for at least 6 months. Outcomes were assessed using nasal anthropometric measurements, Visual Analog Scale (VAS), Global Aesthetic Improvement Scale (GAIS), and Rhinoplasty Outcome Evaluation (ROE). Repeated measures were analyzed with generalized estimating equations (GEE). Results: A total of 10 patients were enrolled, all of whom completed treatment and follow-up. Compared with baseline, VAS and ROE scores showed statistically significant improvement at all post-treatment time points (P < 0.001). GAIS consistently indicated "much improved" or "very much improved" outcomes by both physicians and patients. Objective measurements demonstrated increased nasal length, height, depth, and tip projection, along with decreased nasal width and base width, suggesting enhanced nasal three-dimensional morphology. No adverse events were observed during the study period. Conclusion: In this pilot study, PCL-based filler achieved significant and sustained improvements in nasal morphology and satisfaction. These findings support its clinical value as a safe and effective filler for nonsurgical nasal augmentation, warranting further confirmation in larger, multicenter studies with longer follow-up.